阿司匹林使用与胰腺导管腺癌风险：一项大型病例对照研究。
Aspirin Use and Risk of Pancreatic Ductal Adenocarcinoma: A Large Case-Control Study.
机构信息
Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Department of Internal Medicine, School of Medicine, Hazrat-e Rasool General Hospital, Iran University of Medical Sciences, Tehran, Iran.
出版信息
Arch Iran Med. 2023 Apr 1;26(4):181-185. doi: 10.34172/aim.2023.28.
BACKGROUND
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a five-year survival rate of approximately 5%. The incidence and mortality rates of PDAC are increasing, and the results of medical treatments remain unsatisfactory. Some conflicting evidence suggests that aspirin intake may reduce the risk of PDAC. This study aimed to evaluate the association between regular low-dose aspirin use (80-mg aspirin tablets, 5-7 tablets/week) and the risk of PDAC.
METHODS
This prospective, hospital-based, case-control study was performed on 470 PDAC patients (case group) and 526 sex and age-matched controls, in Tehran, Iran from 2011 to 2018. The participants were interviewed regarding the patterns of aspirin use. Data are expressed as mean±SD or frequency and percentage as appropriate. Differences in frequency between the case and control groups were evaluated based on the analysis of the contingency table (χ test and Fisher's exact test). Propensity score models were designed to calculate odds ratios (OR) and 95% confidence intervals (95% CIs) for PDAC with respect to aspirin use, adjusted for age, sex, smoking status, opium use, diabetes mellitus, place of residence, and family history of cancer in first-degree relatives.
RESULTS
About 60% of PDAC patients were male in this study. Also, 25.2% of PDAC patients had a family history of cancer in one of their first-degree relatives, 21.99% were smokers, 13.9% were opium users, and 11.7% had a history of diabetes. Aspirin was used by 22.77% of PDAC patients and 18.25% of the controls. Ever aspirin use (OR: 1.01, 95% CI: 0.89 - 1.14) was not associated with PDAC.
CONCLUSION
Overall, aspirin use was not associated with a reduced risk of PDAC.
背景
胰腺导管腺癌（PDAC）是最致命的癌症之一，五年生存率约为 5%。PDAC 的发病率和死亡率正在上升，且治疗效果仍不尽如人意。一些相互矛盾的证据表明，阿司匹林的摄入可能会降低 PDAC 的风险。本研究旨在评估规律服用低剂量阿司匹林（80 毫克阿司匹林片剂，每周 5-7 片）与 PDAC 风险之间的关联。
方法
本前瞻性、基于医院的病例对照研究于 2011 年至 2018 年在伊朗德黑兰对 470 名 PDAC 患者（病例组）和 526 名性别和年龄匹配的对照进行。对参与者进行了关于阿司匹林使用模式的访谈。数据以平均值±标准差或频率和百分比表示。使用列联表（卡方检验和 Fisher 确切检验）评估病例组和对照组之间的频率差异。设计倾向评分模型以计算与阿司匹林使用相关的 PDAC 的比值比（OR）和 95%置信区间（95%CI），调整年龄、性别、吸烟状况、鸦片使用、糖尿病、居住地和一级亲属癌症家族史。
结果
在这项研究中，约 60%的 PDAC 患者为男性。此外，25.2%的 PDAC 患者有一级亲属的癌症家族史，21.99%的患者为吸烟者，13.9%的患者为鸦片使用者，11.7%的患者有糖尿病史。22.77%的 PDAC 患者和 18.25%的对照者使用过阿司匹林。曾经使用过阿司匹林（OR：1.01，95%CI：0.89-1.14）与 PDAC 无关。
结论
总体而言，阿司匹林的使用与 PDAC 风险降低无关。
Zotero 插件